EMA’s CHMP Sets Back Vivus’ Qsiva For At Least Two Years In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The EMA has rejected Vivus’ Qsiva for obesity for the second time, citing potential long-term health issues and probably delaying the product’s European launch for at least two years.